Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

References

• Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumour invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost.78, 285–296 (1997).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Jänicke F, Graeff H. Tumour-associated proteases. Fibrinolysis6(Suppl. 4), 3–26 (1992).
   Google Scholar
• Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res.44, 139–266 (1985).
   PubMed Web of Science ®Google Scholar
• Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin. Haematol.8, 291–312 (1995).
   PubMedGoogle Scholar
• Nijziel MR, van Oerle R, Hillen HF, Hamulyák K. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth. J. Med.64, 403–410 (2006).
   PubMedGoogle Scholar
• Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br. J. Haematol.129, 307–321 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen LR, MacLeod CM. A proteolytic enzyme of serum: characterisation, activation, and reaction with inhibitors. J. Gen. Physiol.28, 559–583 (1945).
   PubMed Web of Science ®Google Scholar
• Lewis JH, Ferguson JH. Studies on a proteolytic enzyme system of the blood. Activation of profibrinolysin by serum fibrinolysokinase. Proc. Soc. Exp. Biol. Med.78, 184–188 (1951).
   PubMed Web of Science ®Google Scholar
• Williams JR. The fibrinolytic activity of urine. Br. J. Exp. Pathol.32, 530–537 (1951).
   PubMedGoogle Scholar
• Ploug J, Kjeldgaard NO. Isolation of a plasminogen activator (urokinase) from urine. Arch. Biochem. Biophys.62, 500–501 (1956).
   PubMed Web of Science ®Google Scholar
• Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature261, 595–597 (1976).
   PubMed Web of Science ®Google Scholar
• Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J. Biol. Chem.257, 3276–3283 (1982).
   PubMed Web of Science ®Google Scholar
• Tissot JD, Schneider P, Hauert J, Ruegg M, Kruithof EK, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J. Clin. Invest.70, 1320–1323 (1982).
   PubMedGoogle Scholar
• Wu M, Arimura GK, Yunis AA. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry16, 1913–1908 (1977).
   PubMedGoogle Scholar
• Svanberg L, Astedt B. Release of plasminogen activator from normal and neoplastic endometrium. Experientia35, 818–819 (1979).
   PubMedGoogle Scholar
• Markus G, Takita H, Camiolo SM, Corasanti JG, Evers JL, Hobika GH. Content and characterization of plasminogen activators in human lung tumours and normal lung tissue. Cancer Res.40, 841–848 (1980).
   PubMed Web of Science ®Google Scholar
• Corasanti JG, Celik C, Camiolo SM et al. Plasminogen activator content of human colon tumours and normal mucosae: separation of enzymes and partial purification. J. Natl Cancer Inst.65, 345–351 (1980).
   PubMedGoogle Scholar
• Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell. Biol.100, 86–92 (1985).
   PubMed Web of Science ®Google Scholar
• del Rosso M, Dini G, Fibbi G. Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. Cancer Res.45, 630–636 (1985).
   PubMedGoogle Scholar
• van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem.259, 14914–14921 (1984).
   PubMed Web of Science ®Google Scholar
• Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature217, 253–254 (1968).
   PubMed Web of Science ®Google Scholar
• Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood86, 4007–4024 (1995).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kobayashi H, Kanayama N et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J. Biol. Chem.279(15), 14899–14908 (2004).
   PubMed Web of Science ®Google Scholar
• Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem.281(41), 30439–30446 (2006).
   PubMedGoogle Scholar
• Beaufort N, Seweryn P, de Bentzmann S et al. Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa.Biochem. J.428(3), 473–482 (2010).
   PubMedGoogle Scholar
• Iakhiaev AV, Nalian A, Koenig K, Idell S. Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. Thromb. Res.120(5), 715–725 (2007).
   PubMedGoogle Scholar
• Zorio E, Gilabert-Estelles J, Espana F, Ramon LA, Cosin R, Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem.15(9), 923–929 (2008).
   PubMed Web of Science ®Google Scholar
• Fevang B, Eugen-Olsen J, Yndestad A et al. Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency. Clin. Immunol.131(3), 438–446 (2009).
   PubMedGoogle Scholar
• Miralles F, Parra M, Caelles C, Nagamine Y, Felez J, Munoz-Canoves P. UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-jun n-terminal kinase signaling pathway: requirement of an AP1 enhancer element. Mol. Cell. Biol.18(8), 4537–4547 (1998).
   PubMedGoogle Scholar
• Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML. uPA and PAI-1 in rectal cancer – relationship to radiotherapy and clinical outcome. J. Surg. Res.153(1), 46–53 (2009).
   PubMed Web of Science ®Google Scholar
• Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem.279(12), 11051–11064 (2004).
   PubMed Web of Science ®Google Scholar
• Szabo H, Novak Z, Bauer H et al. Regulation of proteolytic activity induced by inflammatory stimuli in lung epithelial cells. Cell. Mol. Biol.51(Suppl. OL), 729–735 (2005).
   Google Scholar
• Ulisse S, Baldini E, Sorrenti S, D’armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets9(1), 32–71 (2009).
   PubMed Web of Science ®Google Scholar
• Killeen SD, Andrews EJ, Wang JH et al. Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases. Br. J. Cancer96(2), 262–268 (2007).
   PubMedGoogle Scholar
• Zhao Y, Lyons CE Jr, Xiao A et al. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem. Biophys. Res. Commun.369(4), 1215–1220 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am. J. Respir. Cell Mol. Biol.35(6), 705–713 (2006).
   PubMed Web of Science ®Google Scholar
• Binder BR, Mihaly J, Prager GW. uPAR–uPA–PAI-1 interactions and signaling: a vascular biologist’s view. Thromb. Haemost.97(3), 336–342 (2007).
   PubMed Web of Science ®Google Scholar
• Tarui T, Akakura N, Majumdar M et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin α v β 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost.95(3), 524–534 (2006).
   PubMedGoogle Scholar
• Franco P, Vocca I, Carriero MV et al. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and α v β 5 integrin. J. Cell Sci.119(Pt 16), 3424–3434 (2006).
   PubMed Web of Science ®Google Scholar
• Crippa MP. Urokinase-type plasminogen activator. Int. J. Biochem. Cell Biol.39(4), 690–694 (2007).
   PubMed Web of Science ®Google Scholar
• Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing bcl-xl expression levels. J. Biol. Chem.281(26), 17758–17767 (2006).
   PubMedGoogle Scholar
• Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.Oncogene21(16), 2513–2524 (2002).
   PubMedGoogle Scholar
• Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G. The putative tumor suppressor LRP1b, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J. Biol. Chem.276(31), 28889–28896 (2001).
   PubMed Web of Science ®Google Scholar
• Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell. Biol.160(5), 781–791 (2003).
   PubMed Web of Science ®Google Scholar
• Turkmen B, Schmitt M, Schmalfeldt B et al. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis18(5), 686–689 (1997).
   PubMedGoogle Scholar
• Przybylowska K, Smolarczyk K, Kulig A et al. Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer. Cancer Lett.181(1), 23–30 (2002).
   PubMedGoogle Scholar
• Tsai MH, Chen WC, Chen HY, Tsai FJ. Urokinase gene 3´-UTR T/C polymorphism is associated with oral cancer. J. Clin. Lab. Anal.18(5), 276–279 (2004).
   PubMedGoogle Scholar
• Mittal RD, Srivastava DS, Mishra DK. Is urokinase gene 3´-UTR polymorphism associated with prostate cancer? Cancer Biomarkers1(6), 287–292 (2005).
   PubMedGoogle Scholar
• Manchanda PK, Bid HK, Mittal RD. Association of urokinase gene 3´-UTR T/C polymorphism with bladder cancer. Urol. Int.77(1), 81–84 (2006).
   PubMedGoogle Scholar
• Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T. Amplification of urokinase gene in prostate cancer. Cancer Res.61(14), 5340–5344 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Suzuki K, Ihara H, Mogami H, Kazui T, Urano T. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via α(v)β(5) integrin. Semin. Thromb. Hemost.31(3), 356–363 (2005).
   PubMedGoogle Scholar
• Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol.160(1), 237–246 (2002).
   PubMed Web of Science ®Google Scholar
• Gils A, Pedersen KE, Skottrup P et al. Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb. Haemost.90(2), 206–217 (2003).
   PubMedGoogle Scholar
• Vial D, McKeown-Longo PJ. PAI-1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the αvβ5 and α5β1 integrins. J. Cell Sci.121(Pt 10), 1661–1670 (2008).
   PubMedGoogle Scholar
• Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry67(1), 92–98 (2002).
   PubMedGoogle Scholar
• Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost.3(1), 35–45 (2005).
   PubMed Web of Science ®Google Scholar
• Jag UR, Zavadil J, Stanley FM. Insulin acts through FOXO3A to activate transcription of plasminogen activator inhibitor type 1. Mol. Endocrinol.23(10), 1587–1602 (2009).
   PubMedGoogle Scholar
• Smith LH, Coats SR, Qin H et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor a and estrogen receptor b in endothelial cells. Circ. Res.95(3), 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab. Res. Rev.16(3), 192–201 (2000).
   PubMed Web of Science ®Google Scholar
• Norata GD, Banfi C, Pirillo A et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38 MAPK activation and mRNA stabilization. Br. J. Haematol.127(1), 97–104 (2004).
   PubMedGoogle Scholar
• Macfelda K, Weiss TW, Kaun C et al. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1α, tumor necrosis factor-α, transforming growth factor-β and oncostatin M in human cardiac myocytes. J. Mol. Cell. Cardiol.34(12), 1681–1691 (2002).
   PubMed Web of Science ®Google Scholar
• Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-β and tumor necrosis factor-α in endothelial cells. Thromb. Haemost.86(6), 1563–1572 (2001).
   PubMedGoogle Scholar
• Chen HC, Feener EP. Mek1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation. Blood103(7), 2636–2644 (2004).
   PubMedGoogle Scholar
• Liu RM. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid. Redox Signal.10(2), 303–319 (2008).
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Nishimura Y, Shigematsu S et al. Vascular endothelial cell growth factor attenuates actions of transforming growth factor-β in human endothelial cells. J. Biol. Chem.279(53), 55104–55108 (2004).
   PubMedGoogle Scholar
• Kaneko T, Fujii S, Matsumoto A et al. Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler. Thromb. Vasc. Biol.22(5), 855–860 (2002).
   PubMedGoogle Scholar
• Keates AC, Tummala S, Peek RM Jr et al.Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells. Infect. Immun.76(9), 3992–3999 (2008).
   PubMedGoogle Scholar
• Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci.57(1), 25–40 (2000).
   PubMed Web of Science ®Google Scholar
• Stratikos E, Gettins PG. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc. Natl Acad. Sci. USA96(9), 4808–4813 (1999).
   PubMed Web of Science ®Google Scholar
• Dupont DM, Madsen JB, Kristensen T et al. Biochemical properties of plasminogen activator inhibitor-1. Front. Biosci.14, 1337–1361 (2009).
   Google Scholar
• Schroeck F, Arroyo De Prada N, Sperl S, Schmitt M, Viktor M. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (VN): mapping the binding sites on PAI-1 and VN. Biol. Chem.383(7–8), 1143–1149 (2002).
   PubMedGoogle Scholar
• Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat. Struct. Biol.10(7), 541–544 (2003).
   PubMedGoogle Scholar
• Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J. Cell. Physiol.189(1), 23–33 (2001).
   PubMed Web of Science ®Google Scholar
• Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J. Cell. Physiol.220(3), 655–663 (2009).
   PubMedGoogle Scholar
• Durand MK, Bodker JS, Christensen A et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost.91(3), 438–449 (2004).
   PubMed Web of Science ®Google Scholar
• Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp. Biol. Med.229(11), 1090–1096 (2004).
   Google Scholar
• Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem.279(21), 22595–22604 (2004).
   PubMed Web of Science ®Google Scholar
• Milliat F, Sabourin JC, Tarlet G et al. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am. J. Pathol.172(3), 691–701 (2008).
   PubMedGoogle Scholar
• Janicke F, Pache L, Schmitt M et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res.54(10), 2527–2530 (1994).
   PubMed Web of Science ®Google Scholar
• Thomssen C, Harbeck N, Dittmer J et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J. Natl Cancer Inst.101(14), 1028–1029 (2009).
   PubMedGoogle Scholar
• Schmitt M, Sturmheit AS, Welk A, Schnelldorfer C, Harbeck N. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol. Med.120, 245–265 (2006).
   PubMedGoogle Scholar
• Schmitt M, Mengele K, Schueren E et al. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur. J. Cancer43, 835–844 (2007).
   PubMedGoogle Scholar
• Annecke K, Schmitt M, Euler U et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv. Clin. Chem.45, 31–45 (2008).
   PubMed Web of Science ®Google Scholar
• Harbeck N, Schmitt M, Vetter M et al. Prospective biomarker trials Chemo N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer. Breast Care3(Suppl. 2), 11–15 (2008).
   PubMed Web of Science ®Google Scholar
• Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst.94(2), 116–128 (2002).
   PubMed Web of Science ®Google Scholar
• Jänicke F, Schmitt M, Hafter R et al. The urokinase-type plasminogen activator (u-PA) is a potent predictor of early relapse in breast cancer. Fibrinolysis4, 69–78 (1990).
   Google Scholar
• Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer50, 208–214 (1992).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Mengele K, Gkazepis A et al. Assessment of uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 in breast cancer tissue. Historical aspects and future prospects. Breast Care3(Suppl. 2), 3–10 (2008).
   PubMed Web of Science ®Google Scholar
• Becker KF, Schott C, Hipp S et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol.211, 370–378 (2007).
   PubMed Web of Science ®Google Scholar
• Biermann JC, Holzscheiter L, Kotzsch M et al. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumour tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int. J. Mol. Med.21, 251–259 (2008).
   PubMedGoogle Scholar
• Leissner P, Verjat T, Bachelot T et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer6, 216 (2006).
   PubMedGoogle Scholar
• Lamy PJ, Verjat T, Servanton AC, Paye M, Leissner P, Mougin B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA. Correlation with protein expression. Am. J. Clin. Pathol.128, 404–413 (2007).
   PubMedGoogle Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358, 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Pakneshan P, Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin. Cancer Res.10, 3035–3041 (2004).
   PubMedGoogle Scholar
• Pulukuri SM, Estes N, Patel J, Rao JS. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res.67(3), 930–939 (2007).
   PubMed Web of Science ®Google Scholar
• Gao S, Nielsen BS, Krogdahl A et al. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer49(6), 526–538 (2010).
   PubMedGoogle Scholar
• Koshelnick Y, Ehart M, Stockinger H, Binder BR. Mechanisms of signaling through urokinase receptor and the cellular response. Thromb. Haemost.82(2), 305–311 (1999).
   PubMed Web of Science ®Google Scholar
• Cale JM, Lawrence DA. Structure–function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr. Drug Targets8(9), 971–981 (2007).
   PubMed Web of Science ®Google Scholar
• Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr. Pharm. Des.9(19), 1545–1564 (2003).
   PubMed Web of Science ®Google Scholar
• Nykjaer A, Christensen EI, Vorum H et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell. Biol.141(3), 815–828 (1998).
   PubMed Web of Science ®Google Scholar
• Cortese K, Sahores M, Madsen CD, Tacchetti C, Blasi F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS ONE3(11), e3730 (2008).
   PubMed Web of Science ®Google Scholar
• Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncologica49(6), 805–811 (2010).
   PubMed Web of Science ®Google Scholar
• Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis. Markers27(3), 157–172 (2009).
   PubMed Web of Science ®Google Scholar
• Bifulco K, Longanesi-Cattani I, Gargiulo L et al. A urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett.582(7), 1141–1146 (2008).
   PubMedGoogle Scholar
• Resnati M, Pallavicini I, Daverio R, Sidenius N, Bonini P, Blasi F. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J. Immunol. Methods308(1–2), 192–202 (2006).
   PubMedGoogle Scholar
• Gargiulo L, Longanesi-Cattani I, Bifulco K et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem.280(26), 25225–25232 (2005).
   PubMedGoogle Scholar
• Beaufort N, Debela M, Creutzburg S et al. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem.387(2), 217–222 (2006).
   PubMed Web of Science ®Google Scholar
• Beaufort N, Leduc D, Eguchi H et al. The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions. Am. J. Physiol. Lung Cell. Mol. Physiol.292(5), L1263–L1272 (2007).
   Google Scholar
• Leduc D, Beaufort N, de Bentzmann S et al. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis. Infect. Immun.75(8), 3848–3858 (2007).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Mengele K, Napieralski R et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1. Expert Rev. Mol. Diagn. (2010) (In press).
   Google Scholar
• Nielsen BS, Rank F, Illemann M, Lund LR, Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int. J. Cancer120(10), 2086–2095 (2007).
   PubMedGoogle Scholar
• Janicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat.24(3), 195–208 (1993).
   PubMed Web of Science ®Google Scholar
• Carriero MV, Franco P, del Vecchio S et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res.54(20), 5445–5454 (1994).
   PubMedGoogle Scholar
• Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest.74(1), 168–177 (1996).
   PubMedGoogle Scholar
• Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol.183(4), 388–397 (1997).
   PubMedGoogle Scholar
• Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol.157(4), 1219–1227 (2000).
   PubMed Web of Science ®Google Scholar
• Offersen BV, Nielsen BS, Hoyer-Hansen G et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am. J. Pathol.163(5), 1887–1899 (2003).
   PubMedGoogle Scholar
• Castello R, Landete JM, Espana F et al. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb. Res.120(5), 753–762 (2007).
   PubMedGoogle Scholar
• Hurd TC, Sait S, Kohga S et al. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.Ann. Surg. Oncol.14(11), 3117–3124 (2007).
   PubMedGoogle Scholar
• Hildenbrand R, Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int. J. Oncol.34(1), 15–23 (2009).
   PubMedGoogle Scholar
• Wang L, Madigan MC, Chen H et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol.114(2), 265–272 (2009).
   PubMedGoogle Scholar
• Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br. J. Cancer101(3), 432–440 (2009).
   PubMedGoogle Scholar
• Chambers SK, Gertz RE Jr, Ivins CM, Kacinski BM. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer75(7), 1627–1633 (1995).
   PubMed Web of Science ®Google Scholar
• Boss EA, Massuger LF, Thomas CM et al. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res.22(1A), 275–282 (2002).
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Pollow K, Weikel W et al. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin. Chem. Lab. Med.37(1), 47–54 (1999).
   PubMedGoogle Scholar
• Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res.26(2C), 1683–1689 (2006).
   PubMedGoogle Scholar
• Schmalfeldt B, Kuhn W, Reuning U et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res.55(18), 3958–3963 (1995).
   PubMed Web of Science ®Google Scholar
• Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol. Oncol.75(3), 397–400 (1999).
   PubMedGoogle Scholar
• Schmalfeldt B, Prechtel D, Harting K et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res.7(8), 2396–2404 (2001).
   PubMed Web of Science ®Google Scholar
• Gleeson NC, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer72(5), 1670–1672 (1993).
   PubMedGoogle Scholar
• Sandberg T, Eriksson P, Gustavsson B, Casslen B. Differential regulation of the plasminogen activator inhibitor-1 (PAI-1) gene expression by growth factors and progesterone in human endometrial stromal cells. Mol. Hum. Reprod.3(9), 781–787 (1997).
   PubMedGoogle Scholar
• Osmak M, Babic D, Abramic M, Milicic D, Vrhovec I, Skrk J. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas. Neoplasma48(6), 462–467 (2001).
   PubMedGoogle Scholar
• Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res.54(24), 6539–6548 (1994).
   PubMed Web of Science ®Google Scholar
• Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A et al. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur. J. Cancer34(4), 566–569 (1998).
   PubMedGoogle Scholar
• Cozzi PJ, Wang J, Delprado W et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum. Pathol.37(11), 1442–1451 (2006).
   PubMedGoogle Scholar
• Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol.27(2), 180–186 (2009).
   PubMedGoogle Scholar
• Ohta S, Fuse H, Fujiuchi Y, Nagakawa O, Furuya Y. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer. Anticancer Res.23(3C), 2945–2950 (2003).
   PubMedGoogle Scholar
• Gupta A, Lotan Y, Ashfaq R et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol.55(5), 1124–1133 (2009).
   PubMedGoogle Scholar
• Shariat SF, Roehrborn CG, McConnell JD et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J. Clin. Oncol.25(4), 349–355 (2007).
   PubMed Web of Science ®Google Scholar
• Usher PA, Thomsen OF, Iversen P et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer113(6), 870–880 (2005).
   PubMedGoogle Scholar
• van Veldhuizen PJ, Sadasivan R, Cherian R, Wyatt A. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am. J. Med. Sci.312(1), 8–11 (1996).
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate39(2), 123–129 (1999).
   PubMed Web of Science ®Google Scholar
• Morrissey C, True LD, Roudier MP et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin. Exp. Metastasis25(4), 377–388 (2008).
   PubMed Web of Science ®Google Scholar
• Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer78(3), 487–492 (1996).
   PubMedGoogle Scholar
• Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J. Urol.155(3), 858–862 (1996).
   PubMedGoogle Scholar
• Bhuvarahamurthy V, Schroeder J, Kristiansen G et al. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. Oncol. Rep.14(3), 777–782 (2005).
   PubMedGoogle Scholar
• Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J. Urol.174(2), 461–465 (2005).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer82(4), 724–732 (1998).
   PubMedGoogle Scholar
• Span PN, Witjes JA, Grebenchtchikov N et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int.102(2), 177–182 (2008).
   PubMedGoogle Scholar
• Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology61(5), 1053–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Bhuvarahamurthy V, Schroeder J, Denkert C et al.In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Oncol. Rep.12(4), 909–913 (2004).
   PubMedGoogle Scholar
• Skelly MM, Troy A, Duffy MJ et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin. Cancer Res.3(10), 1837–1840 (1997).
   PubMed Web of Science ®Google Scholar
• Herszenyi L, Plebani M, Carraro P et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer86(7), 1135–1142 (1999).
   PubMed Web of Science ®Google Scholar
• Papadopoulou S, Scorilas A, Yotis J et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol.23(3), 170–178 (2002).
   PubMedGoogle Scholar
• Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol.82(3), 184–193 (2003).
   PubMedGoogle Scholar
• Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum. Pathol.41(1), 70–78 (2010).
   PubMedGoogle Scholar
• Zlobec I, Holler S, Tornillo L, Terracciano L, Lugli A. Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. Dis. Colon Rectum52(6), 1114–1121 (2009).
   PubMedGoogle Scholar
• Pyke C, Kristensen P, Ralfkiaer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol.138(5), 1059–1067 (1991).
   PubMed Web of Science ®Google Scholar
• Sato T, Nishimura G, Yonemura Y et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology52(4), 347–352 (1995).
   PubMed Web of Science ®Google Scholar
• Illemann M, Bird N, Majeed A et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int. J. Cancer124(8), 1860–1870 (2009).
   PubMed Web of Science ®Google Scholar
• Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res.54(11), 2900–2907 (1994).
   PubMed Web of Science ®Google Scholar
• Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci.94(1), 43–49 (2003).
   PubMed Web of Science ®Google Scholar
• Beyer BC, Heiss MM, Simon EH et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer106(5), 1026–1035 (2006).
   PubMedGoogle Scholar
• Heiss MM, Babic R, Allgayer H et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol.13(8), 2084–2093 (1995).
   PubMedGoogle Scholar
• Plebani M, Herszenyi L, Carraro P et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin. Exp. Metastasis15(4), 418–425 (1997).
   PubMedGoogle Scholar
• Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbb-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol.18(11), 2201–2209 (2000).
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Delektorskaya VV, Mochal’nikova VV et al. Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology. Bull. Exp. Biol. Med.146(6), 786–790 (2008).
   PubMedGoogle Scholar
• Wang SN, Miyauchi M, Koshikawa N et al. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathol. Int.44(12), 844–849 (1994).
   PubMedGoogle Scholar
• Plebani M, Herszenyi L, Cardin R et al. Cysteine and serine proteases in gastric cancer. Cancer76(3), 367–375 (1995).
   PubMedGoogle Scholar
• Nekarda H, Schlegel P, Schmitt M et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin. Cancer Res.4(7), 1755–1763 (1998).
   PubMedGoogle Scholar
• Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am. J. Pathol.156(2), 567–575 (2000).
   PubMedGoogle Scholar
• Goscinski MA, Suo Z, Florenes VA, Vlatkovic L, Nesland JM, Giercksky KE. FAP-α and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct. Pathol.32(3), 89–96 (2008).
   PubMed Web of Science ®Google Scholar
• Nomiya T, Nemoto K, Miyachi H et al. Significance of plasminogen-activation system in the formation of macroscopic types and invasion in esophageal carcinoma. Anticancer Res.22(5), 2913–2916 (2002).
   PubMed Web of Science ®Google Scholar
• Tang Wh, Friess H, Kekis PB et al. Serine proteinase activation in esophageal cancer. Anticancer Res.21(4A), 2249–2258 (2001).
   PubMedGoogle Scholar
• Torzewski M, Sarbia M, Verreet P et al. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin. Cancer Res.3(12 Pt 1), 2263–2268 (1997).
   PubMedGoogle Scholar
• Sakakibara T, Hibi K, Koike M et al. PAI-1 expression levels in esophageal and colorectal cancers are closely correlated to those in corresponding normal tissues. Anticancer Res.26(6B), 4343–4347 (2006).
   PubMedGoogle Scholar
• Goscinski MA, Suo ZH, Nesland JM et al. Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China. Oncology75(1–2), 49–59 (2008).
   PubMedGoogle Scholar
• Cantero D, Friess H, Deflorin J et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer75(3), 388–395 (1997).
   PubMed Web of Science ®Google Scholar
• Warnecke-Eberz U, Prenzel Kl, Baldus SE et al. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer. Pancreas36(2), 173–177 (2008).
   PubMedGoogle Scholar
• Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am. J. Gastroenterol.88(11), 1928–1933 (1993).
   PubMed Web of Science ®Google Scholar
• Harvey SR, Hurd TC, Markus G et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin. Cancer Res.9(13), 4935–4943 (2003).
   PubMed Web of Science ®Google Scholar
• Nielsen A, Scarlett CJ, Samra JS et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J. Gastroenterol. Hepatol.20(2), 256–263 (2005).
   PubMedGoogle Scholar
• Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol. Int.50(5), 392–397 (2000).
   PubMedGoogle Scholar
• de Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res.58(10), 2234–2239 (1998).
   PubMed Web of Science ®Google Scholar
• Tavian D, de Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer87(5), 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Zheng Q, Tang Zy, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol.126(11), 641–646 (2000).
   PubMedGoogle Scholar
• Zhou Q, Liang LJ, Peng BG, Zhen YY. Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients. J. Cancer25(11), 1433–1438 (2006).
   Google Scholar
• Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J. Pathol.190(2), 190–195 (2000).
   PubMedGoogle Scholar
• Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur. J. Cancer34(8), 1193–1197 (1998).
   PubMedGoogle Scholar
• Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D. Analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res.20(5C), 3975–3981 (2000).
   PubMedGoogle Scholar
• Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA, Berns EM. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck29(4), 341–350 (2007).
   PubMedGoogle Scholar
• Naka T, Kuester D, Boltze C et al. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum. Pathol.39(2), 217–223 (2008).
   PubMedGoogle Scholar
• Shi Z, Stack MS. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem. J.407(2), 153–159 (2007).
   PubMedGoogle Scholar
• Baker EA, Leaper DJ, Hayter JP, Dickenson AJ. Plasminogen activator system in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg.45(8), 623–627 (2007).
   PubMedGoogle Scholar
• Nozaki S, Endo Y, Kawashiri S et al. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol.34(1), 58–62 (1998).
   PubMedGoogle Scholar
• Nagata M, Fujita H, Ida H et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int. J. Cancer106(5), 683–689 (2003).
   PubMed Web of Science ®Google Scholar
• Hundsdorfer B, Zeilhofer HF, Bock KP et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity – clinical relevance and prognostic value. J. Craniomaxillofac. Surg.33(3), 191–196 (2005).
   PubMedGoogle Scholar
• Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH. Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma. Mund Kiefer Gesichtschirurgie8(3), 180–190 (2004).
   PubMedGoogle Scholar
• Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS. Prognostic significance of proteolytic enzymes in human brain tumors. J. Neurooncol.22(2), 101–110 (1994).
   PubMedGoogle Scholar
• Caccamo DV, Keohane ME, McKeever PE. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Mod. Pathol.7(1), 99–104 (1994).
   PubMedGoogle Scholar
• Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res.54(4), 1105–1108 (1994).
   PubMed Web of Science ®Google Scholar
• Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochirurgica140(4), 377–385 (1998).
   PubMedGoogle Scholar
• Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochirurgica145(9), 825–838 (2003).
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Croci D, Prina P et al. Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. Cancer Biol. Ther.5(2), 204–209 (2006).
   PubMed Web of Science ®Google Scholar
• Kono S, Rao JS, Bruner JM, Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J. Neuropathol. Exp. Neurol.53(3), 256–262 (1994).
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Johansson M, Sandstrom J, Bergenheim AT, Henriksson R. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int. J. Dev. Neurosci.17(5–6), 473–481 (1999).
   PubMedGoogle Scholar
• Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am. J. Pathol.147(1), 114–123 (1995).
   PubMedGoogle Scholar
• Iwadate Y, Hayama M, Adachi A et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res.28(1B), 415–418 (2008).
   PubMedGoogle Scholar
• Yamamoto M, Sawaya R, Mohanam S et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.Cancer Res.54(14), 3656–3661 (1994).
   PubMed Web of Science ®Google Scholar
• Zhang X, Bu XY, Zhen HN, Fei Z, Zhang JN, Fu LA. Expression and localisation of urokinase-type plasminogen activator gene in gliomas. J. Clin. Neurosci.7(2), 116–119 (2000).
   PubMed Web of Science ®Google Scholar
• Chu QD, Hurd TC, Harvey S et al. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis. Diagn. Mol. Pathol.13(4), 241–246 (2004).
   PubMedGoogle Scholar
• Horvatic Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomic-Brzac H, Kulic A. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wiener Klinische Wochenschrift118(19–20), 601–609 (2006).
   PubMedGoogle Scholar
• Ulisse S, Baldini E, Toller M et al. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur. J. Cancer42(15), 2631–2638 (2006).
   PubMedGoogle Scholar
• Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol. Rep.10(3), 635–639 (2003).
   PubMedGoogle Scholar
• de Vries TJ, Mooy CM, van Balken MR et al. Components of the plasminogen activation system in uveal melanoma – a clinico-pathological study. J. Pathol.175(1), 59–67 (1995).
   PubMed Web of Science ®Google Scholar
• Gershtein ES, Medvedeva SV, Babkina IV, Kushlinskii NE, Trapeznikov NN. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bull. Exp. Biol. Med.132(1), 670–674 (2001).
   PubMedGoogle Scholar
• Hanekom GS, Stubbings HM, Kidson SH. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma. Cancer Detect. Prevent.26(1), 50–59 (2002).
   PubMedGoogle Scholar
• Ito Y, Takeda T, Kobayashi T et al. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. Anticancer Res.16(1), 81–89 (1996).
   PubMedGoogle Scholar
• Kushlinskii NE, Gershtein ES, Kazantseva IA et al. [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]. Vestn. Akad. Med. Nauk SSSR(5), 32–34 (2001).
   Google Scholar
• Choong PF, Ferno M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer69(4), 268–272 (1996).
   PubMed Web of Science ®Google Scholar
• Benassi MS, Ponticelli F, Azzoni E et al. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol. Histopathol.22(9), 1017–1024 (2007).
   PubMedGoogle Scholar
• Kushlinskii NE, Yusifov AI, Gershtein ES, Solov’ev YN, Trapeznikov NN. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. Bull. Exp. Biol. Med.132(2), 780–782 (2001).
   PubMedGoogle Scholar
• Hakel C, Ueda Y, Tsuchya H, Herrera A, Blasius S, Roessner A. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. Zentralblatt fuer Pathologie140(4–5), 363–369 (1994).
   PubMedGoogle Scholar
• Hackel C, Czerniak B, Ayala AG, Radig K, Roessner A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer79(1), 53–58 (1997).
   PubMed Web of Science ®Google Scholar
• Thewes M, Elsner E, Wessner D, Engst R, Ring J. The urokinase plasminogen activator system in angiosarcoma, Kaposi’s sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study. Int. J. Dermatol.39(3), 188–191 (2000).
   PubMedGoogle Scholar
• Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. Anticancer Res.20(5A), 3031–3036 (2000).
   PubMedGoogle Scholar
• Taubert H, Wurl P, Greither T et al. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br. J. Cancer102(4), 731–737 (2010).
   PubMedGoogle Scholar
• Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res.51(13), 3522–3525 (1991).
   PubMed Web of Science ®Google Scholar
• Hofmann HS, Bartling B, Simm A et al. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. Oncol. Rep.16(3), 587–595 (2006).
   PubMed Web of Science ®Google Scholar
• Volm M, Mattern J, Koomagi R. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol. Rep.6(3), 611–615 (1999).
   PubMedGoogle Scholar
• Salden M, Splinter TA, Peters HA et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann. Oncol.11(3), 327–332 (2000).
   PubMedGoogle Scholar
• Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res.54(17), 4671–4675 (1994).
   PubMed Web of Science ®Google Scholar
• Werle B, Kotzsch M, Lah TT et al. Cathepsin B, plasminogen activator-inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res.24(6), 4147–4161 (2004).
   PubMed Web of Science ®Google Scholar
• Zekanowska E, Cieslinski K, Rosc D. Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer. Pneumonologia i Alergologia Polska72(9–10), 409–414 (2004).
   PubMedGoogle Scholar
• Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. Boll. Soc. Ital. Biol. Sper.72(11–12), 331–340 (1996).
   PubMedGoogle Scholar
• Pedersen H, Grondahl-Hansen J, Francis D et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res.54(1), 120–123 (1994).
   PubMed Web of Science ®Google Scholar
• Sgier D, Zuberbuehler K, Pfaffen S, Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng. Des. Sel.23(4), 261–269 (2010).
   PubMed Web of Science ®Google Scholar